What is on the differential diagnosis for Ovarian Cancer?

Key differentials include Benign ovarian cyst (functional, dermoid, endometrioma), Endometriosis / endometrioma, Tubo-ovarian abscess, Diverticular abscess, GI malignancy with ovarian metastasis (Krukenberg), Primary peritoneal carcinomatosis, Ascites from cirrhosis or heart failure.

What are the high-yield PANCE pearls for Ovarian Cancer?

Screening with CA-125 and TVUS does NOT reduce mortality in average-risk women — not recommended (UKCTOCS and PLCO trials). All women with epithelial ovarian, fallopian tube, or peritoneal cancer should be referred for genetic counseling and BRCA/HRD testing — affects family screening and PARP inhibitor eligibility. The 'ovarian cancer triad' of bloating, early satiety, and urinary symptoms persisting >2 weeks warrants pelvic exam, TVUS, and CA-125. Most ovarian cancers (~70%) present at advanced stage (III-IV) because of vague early symptoms — 5-year survival ~30%. Krukenberg tumor: bilateral ovarian metastases with signet-ring cells from a GI primary (usually gastric) — always evaluate GI tract if histology suspicious. Opportunistic salpingectomy during benign gyn surgery reduces future ovarian cancer risk and is now recommended by ACOG.

Reproductive · PANCE / PANRE

Ovarian Cancer

Written & clinically reviewed by Ryan Busch, PA-C · Updated August 2026 · Report an error

'Silent' epithelial malignancy of the ovary/fallopian tube — vague abdominal symptoms; late diagnosis is the rule.

Also known as: ovarian cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, BRCA

Overview

Heterogeneous malignancy of the ovary, fallopian tube, or peritoneum. Epithelial subtypes (~90%) include high-grade serous (most common and aggressive), endometrioid, clear cell, mucinous, and low-grade serous. Non-epithelial tumors include germ cell (younger patients) and sex cord-stromal tumors. Most 'ovarian cancers' actually originate from the distal fallopian tube fimbriae.

Epidemiology

Fifth leading cause of cancer death in US women; ~20,000 new cases/year, ~13,000 deaths. Lifetime risk ~1.3% in general population; ~40% with BRCA1, ~15-25% with BRCA2. Median age at diagnosis ~63.

Try a board-style Ovarian Cancer question

Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.

Question 1ReproductiveMedium

A postmenopausal woman has bloating, early satiety, and an adnexal mass. Which of the following best explains why symptoms are often advanced at diagnosis?

AInsidious peritoneal spread before detection
BHematogenous spread to bone before symptoms
CImmediate torsion after cyst formation
DLymphatic spread along the inguinal chain

Reveal answer & full explanation

Correct answer: A — Insidious peritoneal spread before detection

AInsidious peritoneal spread before detection✓
BHematogenous spread to bone before symptoms
CImmediate torsion after cyst formation
DLymphatic spread along the inguinal chain

Why Insidious peritoneal spread before detection is correct

Ovarian cancer spreads transcoelomically across the peritoneum while producing only vague bloating and early satiety.
These nonspecific symptoms and the absence of an effective screening test delay recognition until disease is advanced.
A postmenopausal adnexal mass with these symptoms is concerning for malignancy and ascites.

Why the others are wrong

Lymphatic spread along the inguinal chain — ovarian lymphatic drainage follows the gonadal vessels to pelvic and para-aortic nodes; inguinal spread is the vulvar pattern and would not produce bloating and early satiety.
Hematogenous spread to bone before symptoms — bone metastases from ovarian cancer are rare and late, and would announce themselves with skeletal pain rather than the abdominal distention seen here.
Immediate torsion after cyst formation — Torsion causes acute severe pain that prompts EARLY presentation, the opposite of an insidious advanced course (acute-vs-insidious trap).

🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full Ovarian Cancer outline — plus all 514 diagnoses, 6,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Start your 7-day free trial → Sign in

Free to start · No credit card · Cancel anytime

Risk factors

Family history; BRCA1/BRCA2 mutations
Lynch syndrome (HNPCC)
Increased lifetime ovulations: nulliparity, early menarche, late menopause, infertility
Endometriosis (clear cell, endometrioid types)
Hormone therapy (modest)
Older age
Protective: multiparity, breastfeeding, combined OCP use (~50% reduction), tubal ligation, salpingectomy

Pathophysiology

High-grade serous carcinomas arise from serous tubal intraepithelial carcinoma (STIC) in fallopian tube fimbriae, with early peritoneal dissemination explaining late stage at diagnosis. TP53 mutations are nearly universal in HGSC. BRCA1/2 mutations impair homologous recombination DNA repair — confer hereditary risk and PARP inhibitor sensitivity.

Clinical presentation

Symptoms

Vague abdominal/pelvic discomfort, bloating
Early satiety, decreased appetite
Urinary urgency or frequency
Constipation or change in bowel habits
Symptoms persistent (>2 weeks) and new (within 12 months) — should prompt evaluation
Late: ascites, abdominal distension, weight loss, dyspnea (pleural effusion)

Signs / physical exam

Adnexal mass on bimanual or rectovaginal exam
Ascites, fluid wave
Sister Mary Joseph nodule (periumbilical lymph node metastasis)
Pleural effusion
Lymphadenopathy

Differential diagnosis

Benign ovarian cyst (functional, dermoid, endometrioma) — Simple cyst on ultrasound, normal CA-125; younger patients
Endometriosis / endometrioma — Cyclic pain, dysmenorrhea, dyspareunia; 'chocolate cyst'
Tubo-ovarian abscess — Fever, leukocytosis, sexually active; PID context
Diverticular abscess — LLQ pain, fever; CT diagnostic
GI malignancy with ovarian metastasis (Krukenberg) — Bilateral ovarian masses with signet-ring cells from gastric primary; EGD/colonoscopy
Primary peritoneal carcinomatosis — Diffuse peritoneal disease without primary ovarian mass
Ascites from cirrhosis or heart failure — Hepatic stigmata, cardiac history; SAAG calculation

Diagnostic workup

Diagnostic criteria

USPSTF 2018: Screening for ovarian cancer in asymptomatic average-risk women NOT recommended (Grade D). Genetic counseling/testing for women with personal or family history suggestive of BRCA/Lynch. FIGO 2014 staging: I (confined to ovaries/tubes), II (pelvic extension), III (peritoneal beyond pelvis ± nodes), IV (distant).

Labs

CA-125 — useful for postmenopausal women (better specificity); less reliable premenopausal due to other causes of elevation
HE4 (with CA-125 in ROMA algorithm)
Premenopausal mass: AFP, β-hCG, LDH (germ cell markers), inhibin (granulosa cell)
CEA, CA 19-9 if mucinous tumor suspected or to evaluate GI primary
CBC, BMP, LFTs
Genetic testing — BRCA1/BRCA2 and broader hereditary cancer panel recommended for ALL women with epithelial ovarian, fallopian tube, or primary peritoneal cancer

Imaging

Transvaginal ultrasound — characterizes adnexal mass (size, septations, solid components, vascularity, bilaterality, ascites)
CT abdomen/pelvis or MRI — staging, peritoneal disease
CT chest if suspicious findings
Surgical staging is required — laparotomy with comprehensive staging (peritoneal washings, omentectomy, lymphadenectomy)

Diagnostic algorithm

Feature	Concerning for Malignancy	Reassuring
Patient age	Postmenopausal	Premenopausal
Size	>10 cm	<5 cm
Composition	Solid or mixed; thick septations	Simple cystic
Vascularity	Internal flow on Doppler	No internal flow
Bilaterality	Bilateral masses	Unilateral
Ascites	Present	Absent
CA-125	Elevated, especially postmenopausal	Normal
Family history	BRCA, Lynch, ovarian/breast	None
Action	Gyn-onc referral, surgical staging	Surveillance or simple cystectomy

Risk stratification of an adnexal mass — features pointing toward malignancy.

Treatment

First-line

Primary cytoreductive (debulking) surgery — TH/BSO, omentectomy, peritoneal biopsies, lymphadenectomy; goal complete or optimal (<1 cm residual) cytoreduction
Adjuvant chemotherapy — carboplatin + paclitaxel × 6 cycles
Stage IA grade 1 may not require chemotherapy
Neoadjuvant chemotherapy followed by interval debulking — for poor surgical candidates or unresectable disease

Maintenance therapy

PARP inhibitors — olaparib, niraparib, rucaparib — after response to platinum chemotherapy
Particularly effective in BRCA-mutated or HRD-positive tumors
Bevacizumab — angiogenesis inhibitor, used during and after chemo in advanced disease

Recurrent disease

Platinum-sensitive (>6 months since last platinum): retreat with platinum doublet
Platinum-resistant: single-agent chemotherapy (liposomal doxorubicin, topotecan, gemcitabine, weekly paclitaxel) ± bevacizumab
Targeted therapy based on molecular profile

Risk-reducing surgery

BRCA1: risk-reducing salpingo-oophorectomy by age 35-40 after childbearing
BRCA2: by age 40-45
Lynch syndrome: discuss after childbearing complete
Opportunistic salpingectomy at time of benign gyn surgery for average-risk women (ACOG recommends)

Germ cell tumors

Fertility-sparing unilateral salpingo-oophorectomy + staging often appropriate
BEP chemotherapy (bleomycin, etoposide, cisplatin) for most
Excellent cure rates

Complications

Bowel obstruction (peritoneal spread) — common in advanced disease
Malignant ascites, pleural effusion
Chemo toxicity (neuropathy, alopecia, cytopenias)
VTE — increased risk
Recurrence (~70% of advanced-stage cases)
Premature menopause from BSO

PANCE pearls

Screening with CA-125 and TVUS does NOT reduce mortality in average-risk women — not recommended (UKCTOCS and PLCO trials).
All women with epithelial ovarian, fallopian tube, or peritoneal cancer should be referred for genetic counseling and BRCA/HRD testing — affects family screening and PARP inhibitor eligibility.
The 'ovarian cancer triad' of bloating, early satiety, and urinary symptoms persisting >2 weeks warrants pelvic exam, TVUS, and CA-125.
Most ovarian cancers (~70%) present at advanced stage (III-IV) because of vague early symptoms — 5-year survival ~30%.
Krukenberg tumor: bilateral ovarian metastases with signet-ring cells from a GI primary (usually gastric) — always evaluate GI tract if histology suspicious.
Opportunistic salpingectomy during benign gyn surgery reduces future ovarian cancer risk and is now recommended by ACOG.

References

USPSTF 2018 — Screening for Ovarian Cancer: USPSTF Recommendation Statement (JAMA 2018)
NCCN Ovarian 2024 — NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer
ACOG PB 174 — ACOG Practice Bulletin No. 174: Evaluation and Management of Adnexal Masses
SGO 2019 — Genetic Testing for Ovarian Cancer: SGO Clinical Practice Statement

Practice Reproductive questions on FirstPassPA

Turn this outline into retention. 6,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Answer the free question above → Get today's free question →

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.